RALEIGH — Raleigh-headquartered Endpoint Clinical has acquired Boston-based Bluefin, expanding its clinical-trial technology business into supply forecasting and planning.
The companies announced the completed acquisition Sept. 14. Financial terms were not included in the announcement.
Endpoint provides randomization and trial supply management software used to manage patient enrollment, treatment assignments and clinical supplies. Bluefin’s platform forecasts demand, evaluates supply scenarios, plans distribution and helps trial sponsors manage supply risk.
Bluefin will continue to operate independently and remain compatible with randomization and trial supply management systems across the industry. Endpoint said it will support Bluefin with project management, implementation, quality and customer-support capabilities.
Endpoint says it employs more than 600 people globally, with offices in the United States, Europe and Asia. Its headquarters is at 8045 Arco Corporate Drive in Raleigh.
Arsenal Capital Partners acquired Endpoint in 2024. The private-equity firm said the Bluefin deal extends Endpoint beyond trial-execution software into clinical-supply planning.
Featured image: An official Bluefin product rendering showing the acquired clinical-supply forecasting platform with demo data. Credit: Bluefin Clinical.
